Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor?

Blood

Volumn 114, Issue 4, 2009, Pages 759-763

  Barbui, Tiziano ^a   Carobbio, Alessandra ^a   Rambaldi, Alessandro ^a   Finazzi, Guido ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBIN; HEMOSTATIC AGENT; HEPARIN COFACTOR II; HYDROXYUREA;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTHEMIA; THROMBOSIS; VASCULAR DISEASE; AGED; ARTICLE; COHORT ANALYSIS; DISEASE PREDISPOSITION; FOLLOW UP; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE SUSCEPTIBILITY; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; LEUKOCYTOSIS; MIDDLE AGED; PLATELET COUNT; POLYCYTHEMIA VERA; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 67649402606     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-206797     Document Type: Review

References (31)

1. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8:556-562. (Pubitemid 20087557)
2. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23: 2224-2232. (Pubitemid 46218714)
3. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005; 353:85-86. (Pubitemid 41007812)
4. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109:5104-5111. (Pubitemid 46890524)
5. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89: 215-232. (Pubitemid 38796497)
6. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica. 2008; 93:1412-1414.
7. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310-2313. (Pubitemid 46425868)
8. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008; 26:2732-2736.
9. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109: 2446-2452. (Pubitemid 46425887)
10. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
11. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112:3135-3137.
12. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109-2123.
13. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocytemia beyond the first decade: life expectancy, long-term complication rates and prognostic factors. Mayo Clin Proc. 2006;81:159-166.
14. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia [letter]. Blood. 2007;109:4105. (Pubitemid 46641767)
15. Caramazza D, Caracciolo C, Barone R, et al. Correlation between leukocytosis and thrombosis in Philadelphia negative chronic myeloproliferative neoplasms. Ann Hematol. Prepublished on February 13, 2009, as DOI 10.1007/s00277-009-0706-x.
16. Hsiao H, Yang MY, Liu YC, et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol. 2007;35:1704-1707. (Pubitemid 47633773)
17. Lowe GD. Common risk factors for both arterial and venous thrombosis. Br J Haematol. 2008; 140:488-495.
18. Tzoulaki I, Murray GD, Lee AJ, et al. C-reactive protein, interleukin-6 and soluble adhesion molecules as predictors of progressive peripheral arherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005;112:976-983. (Pubitemid 41170265)
19. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
20. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 muational status. Haematologica. 2006; 91:169-175. (Pubitemid 43304135)
21. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007;35:702-711. (Pubitemid 46601748)
22. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostatsis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96: 4261-4266.
23. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte- platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523-530. (Pubitemid 40592168)
24. Marchetti M, Castoldi E, Spronk HMH, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112: 4061-4068.
25. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353:33-45. (Pubitemid 41007805)
26. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065-3072.
27. Kiladjian JJ, Chomienne C, Fenaux P. Interferonalfa therapy in bcr-abl negative myeloproliferative neoplasms. Leukemia. 2008;22:1990-1998.
28. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet (ELN) consensus conference. Blood. 2009;113:4829-4833.
29. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol. 2005;25: 658-670.
30. Okpala I. The intriguing contribution of white blood cells to sickle cell disease: a red cell disorder. Blood Rev. 2004;18:65-73. (Pubitemid 38200501)
31. Kundi M. Causality and the interpretation of epidemiological evidence. Environ Health Perspect. 2006;114:969-974.